Skinvisible (SKVI) Net Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.02 Bn | 629.26 Bn | 17.26 Bn | 38.95% |
| 2 | AbbVie | 443.38 Bn | 436.81 Bn | 12.70 Bn | -49.89% |
| 3 | Merck | 368.22 Bn | 361.07 Bn | 12.21 Bn | 33.59% |
| 4 | Novartis Ag | 270.16 Bn | 262.47 Bn | 11.24 Bn | 38.53% |
| 5 | Pfizer | 158.63 Bn | 146.93 Bn | 10.94 Bn | -51.84% |
| 6 | Sanofi | 52.92 Bn | 45.54 Bn | 10.79 Bn | 1.06% |
| 7 | Revolution Medicines | 44.49 Bn | 44.49 Bn | - | - |
| 8 | Incyte | 25.22 Bn | 20.69 Bn | 1.57 Bn | 18.67% |
| 9 | United Therapeutics | 21.17 Bn | 18.51 Bn | 683.80 Mn | 95.24% |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 27.74% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.74% |
| Mar 31, 2026 | 74.94% |
| Dec 31, 2025 | 26.89% |
| Sep 30, 2025 | 26.33% |
| Jun 30, 2025 | -27.15% |
| Mar 31, 2025 | 27.54% |
| Dec 31, 2024 | -16.68% |
| Sep 30, 2024 | -3.50% |
| Jun 30, 2024 | -42.34% |
| Mar 31, 2024 | 32.20% |
| Dec 31, 2023 | -81.32% |
| Sep 30, 2023 | 40.84% |
| Jun 30, 2023 | -42.56% |
| Mar 31, 2023 | -128.25% |
| Dec 31, 2022 | -238.78% |
| Sep 30, 2022 | -71.45% |
| Jun 30, 2022 | 338.07% |
| Mar 31, 2022 | -341.11% |
| Dec 31, 2021 | 41.06% |
| Sep 30, 2021 | -44.19% |